Metastatic castration-resistant prostate cancer in
patients whose disease has progressed during or after
treatment with a docetaxel-containing chemotherapy
regimen (in combination with prednisone or
prednisolone) | Metastatic castration-resistant prostate
cancer in patients who are asymptomatic or mildly
symptomatic after failure of androgen deprivation
therapy in whom chemotherapy is not yet clinically
indicated (in combination with prednisone or
prednisolone) | High risk metastatic hormone-sensitive
prostate cancer in newly diagnosed patients (in
combination with androgen deprivation therapy, and
prednisone or prednisolone)
▶BY MOUTH
▶Adult: 1 g once daily, for dose of concurrent prednisone
or prednisolone—consult product literature
PDF page 1019
Diabetes (increased risk of hyperglycaemia—
monitor blood sugar frequently). history of cardiovascular
disease
CAUTIONS, FURTHER INFORMATION
▶Cardiovascular disease Correct hypertension and
hypokalaemia before treatment (if significant risk of
congestive heart failure, such as history of cardiac failure,
uncontrolled hypertension or cardiac events, consult
product literature for management and increased
monitoring).
PDF page 1019
NICE decisions
▶Abiraterone for castration-resistant metastatic prostate
cancer previously treated with a docetaxel-containing
regimen (updated July 2016) NICE TA259
Abiraterone in combination with prednisone or
prednisolone is recommended as an option for the
treatment of castration-resistant metastatic prostate
cancer only if:
. their disease has progressed on or after one docetaxel-
containing chemotherapy regimen, and
. the manufacturer provides abiraterone in accordance
with the commercial access arrangement as agreed with
NHS England.
Patients currently receiving abiraterone in combination
with prednisone or prednisolone whose disease does not
meet the first criteria should be able to continue therapy
until they and their clinician consider it appropriate to
stop.
www.nice.org.uk/guidance/ta259
▶Abiraterone for treating metastatic hormone-relapsed
prostate cancer before chemotherapy is indicated (updated
July 2016) NICE TA387
Abiraterone, in combination with prednisone or
prednisolone, is recommended, within its marketing
authorisation, as an option for treating metastatic
hormone-relapsed prostate cancer:
. in people who have no or mild symptoms after androgen
deprivation therapy has failed, and before chemotherapy
is indicated
. only when the manufacturer provides abiraterone in
accordance with the commercial access arrangement as
agreed with NHS England.
www.nice.org.uk/guidance/ta387
Scottish Medicines Consortium (SMC) decisions
SMC No. 764/12
The Scottish Medicines Consortium has advised (August
2012) that abiraterone acetate (Zytiga ®), in combination
with prednisone or prednisolone, is accepted for restricted
use within NHS Scotland for the treatment of metastatic
castration-resistant prostate cancer in patients whose
disease has progressed during or after treatment with
docetaxel-containing chemotherapy regimen, and have
received only one prior chemotherapy regimen. This
advice is contingent upon the continuing availability of
the patient access scheme in NHS Scotland.
SMC No. 873/13
The Scottish Medicines Consortium has advised (October
2015) that abiraterone acetate (Zytiga ®) in combination
with prednisone or prednisolone, is accepted for use
within NHS Scotland for the treatment of metastatic
castration-resistant prostate cancer in patients who are
asymptomatic or mildly symptomatic, after failure of
androgen deprivation therapy in whom chemotherapy is
not yet clinically indicated. This advice is contingent upon
the continuing availability of the patient access scheme in
NHS Scotland or a list price that is equivalent or lower.
SMC No. SMC2215
The Scottish Medicines Consortium has advised (January
2020) that abiraterone acetate (Zytiga ®), in combination
with prednisone or prednisolone and androgen
deprivation therapy, is accepted for use within NHS
Scotland for the treatment of newly diagnosed high-risk
metastatic hormone-sensitive prostate cancer in adults.
This advice is contingent upon the continuing availability
of the patient access scheme in NHS Scotland or a list price
that is equivalent or lower.
PDF page 1020
